Genelabs, GlaxoSmithKline deal

GlaxoSmithKline extended to Dec. 29 from Dec. 12 its $1.30 per share tender offer to acquire Genelabs. At Dec. 12, there were 35.1 million shares (79%) tendered (see BioCentury, Nov. 3). ...